Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGADIR: atezolizumab + EIK1001 with immunogenic radiotherapy in advanced solid tumors
2023-509492-16-00Phase 2Authorised
- Sponsor
- Institut Bergonié
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab and BDB001 in pancreatic cancer (PC), cancer, non-small cell lung cancer (NSCLC) and 3 more (6 arms), sponsored by Institut Bergonié. Primary endpoints: Disease control rate within 24 weeks and 6-month progression-free rate. Planned start Aug 2024; status: authorised.
02
Drugs
atezolizumabBDB001
03
Conditions
pancreatic cancer (PC)cancernon-small cell lung cancer (NSCLC)soft tissue sarcoma (STS)bladder cancer
Beyond the preview
Go deeper on 2023-509492-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509492-16-00.